Biogen's stock jumps 42% after FDA staff says it has enough data to support approving Alzheimer's drug
By Berkeley Lovelace & Berkeley Lovelace Jr.
FDA scientists appear to offer major endorsement of Biogen's controversial Alzheimer's treatment
By Adam Feuerstein & Damian Garde